Latest Industry Insights

To learn more about new technologies being developed for drug discovery and cell therapy, Technology Networks spoke to bit.bio's Dr. Farah Patell-Socha and Furqan Iqbal.

In this opinion piece, Eric Rhodes, CEO of ERS Genomics, shares his roundup of some of the most exciting innovations in synthetic biology right now.

In this interview, we spoke to Rachel Marty Pyke PhD, manager of bioinformatics science at Personalis, to find out how machine learning can be used to detect genomic instability as a biomarker for cancer immunotherapy.

We spoke to Dr. Audrey Dubourg, product manager at CN Bio to find out more about how its organ-on-chip platform could bridge the gap between the current 2D models and animal models, providing human-relevant insights into diseases such as non-alcoholic steatohepatitis.

In this piece, Adam Clore explores how smart automation can help synthetic biology companies become more resilient.

To find out more about how early-stage funding could improve longevity research, we had the pleasure of speaking to Garri Zmudze, executive director of the Longevity Science Foundation.

Learn how automation can help to obtain high-quality next generation sequencing research data.

Technology Networks spoke to Jason Ornstein and Barry Holtz to learn how Synshark and Phylloceuticals are working together to address current challenges associated with squalene supply and access.

In this opinion piece, Dan Gibson discusses some of the common pitfalls in the DNA synthesis field and explores how a new generation of synthesis technologies could overcome these challenges.

Dr. Christian Landles explains why it is so challenging to develop therapeutics for rare diseases such as HD, and discusses the potential of approaches that target mutant huntingtin protein to improve treatment options for HD patients.